New Blood Thinners May Slow Cognitive Decline in Alzheimer’s Patients

A recent study shows that patients with Alzheimer’s disease and atrial fibrillation who take newer oral anticoagulants (NOACs) experience a slower yearly decline in cognitive function compared with those on warfarin or no anticoagulants. Researchers measured cognitive trajectories over time and found the difference modest each year, yet cumulative effects could become clinically meaningful. The study focused on patients already at risk for stroke, highlighting an additional benefit of NOACs beyond their primary role in preventing clot formation. The data suggest that clinicians may weigh NOACs as a potential strategy to preserve cognition in this vulnerable population, alongside their established stroke‑prevention use.